Conditions: Non-Squamous Non-Small Cell Lung Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 208
Healthy volunteers: no

Brief summary:
This open-label, single arm study will evaluate the safety and efficacy of Tarceva (erlotinib) as first-line therapy in participants with stage IV or recurrent non-small cell lung cancer who harbour epidermal growth factor receptor (EGFR) mutations. All participants will receive Tarceva 150 mg daily orally until disease progression or unacceptable toxicity occurs. At the investigator's discretion, participants may receive Tarceva beyond disease progression.

Detailed description:

Arms:
arm 1: Erlotinib 150 mg daily

Interventions: intervention 1: Erlotinib
Intervention descriptions: intervention 1: Erlotinib 150 mg was administered orally daily until disease progression or unacceptable toxicity.

Protocol document: